Fate Therapeutics Inc/ US31189P1021 /
2024-03-28 5:46:21 PM | Chg. +0.1350 | Volume | Bid5:46:58 PM | Ask5:46:58 PM | High | Low |
---|---|---|---|---|---|---|
7.4750USD | +1.84% | 820,239 Turnover: 5.43 mill. |
7.4700Bid Size: 500 | 7.4800Ask Size: 200 | 7.6500 | 7.2300 |
GlobeNewswire
03-19
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Pla...
GlobeNewswire
03-05
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
02-26
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GlobeNewswire
02-15
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial R...
Newsfile Corp
02-15
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
GlobeNewswire
02-02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-08
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients wi...
GlobeNewswire
2023-12-13
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-08
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
GlobeNewswire
2023-11-04
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Beh...
GlobeNewswire
2023-11-02
SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encour...
GlobeNewswire
2023-10-25
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
GlobeNewswire
2023-09-10
Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, In...
GlobeNewswire
2023-08-28
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Beh...
GlobeNewswire
2023-08-21
SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encour...
GlobeNewswire
2022-02-28
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operati...
GlobeNewswire
2022-02-16
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial R...
GlobeNewswire
2022-01-10
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Pr...
GlobeNewswire
2021-12-13
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR...